JAK Inhibition Decreases the Autoimmune Burden in Down Syndrome

    August 2024 in “ eLife ”
    Angela L. Rachubinski, Elizabeth Wallace, Emily Gurnee, Belinda A Enriquez Estrada, Kayleigh R Worek, Keith P. Smith, Paula Araya, Katherine A. Waugh, Ross E. Granrath, Eleanor Britton, Hannah R. Lyford, Micah G. Donovan, Neetha Paul Eduthan, Amanda A. Hill, Barry Martin, Kelly D. Sullivan, Lina Patel, Deborah J. Fidler, Matthew D. Galbraith, Cory A. Dunnick, David A. Norris, Joaquı́n M. Espinosa
    TLDR JAK inhibition may help manage autoimmune conditions in Down syndrome.
    The study examines the effects of JAK inhibition using tofacitinib on autoimmune conditions in individuals with Down syndrome (DS). Interim results from a Phase II clinical trial with 10 participants showed that tofacitinib was well-tolerated and led to improvements in skin conditions such as alopecia areata, psoriasis, and atopic dermatitis. The treatment reduced interferon and cytokine scores and pathogenic autoantibodies without significant immune suppression. The findings suggest that JAK inhibition could be a promising strategy for managing autoimmune conditions in DS, although further research is needed to explore its broader effects on DS-related developmental and clinical features.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results